Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: A comprehensive analysis of 3,671 families

International Journal of Cancer

Volumn 135, Issue 1, 2014, Pages 69-77

  Steinke, Verena ^a   Holzapfel, Stefanie ^a   Loeffler, Markus ^b   Holinski Feder, Elke ^c,d   Morak, Monika ^c,d   Schackert, Hans K ^e   Görgens, Heike ^e   Pox, Christian ^f   Royer Pokora, Brigitte ^g   Von Knebel Doeberitz, Magnus ^h,i   Büttner, Reinhard ^j   Propping, Peter ^a   Engel, Christoph ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Center of Medical Genetics and Primary Health Care   (Armenia)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Bethesda guidelines; clinical diagnostic criteria; HNPCC; lynch syndrome; mismatch repair defects

Indexed keywords

BETHESDA GUIDELINES; CLINICAL DIAGNOSTIC CRITERIA; HNPCC; LYNCH SYNDROME; MISMATCH-REPAIR DEFECTS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS;

EID: 84899456187     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28650     Document Type: Article

References (18)

1. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-9.
2. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009; 41: 112-7.
3. Lamberti C, Mangold E, Pagenstecher C, et al. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 2006; 74: 58-67.
4. Boland CR, Shike M,. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 2010; 138: 2197 e1-7.
5. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18.
6. Vasen HF, Mecklin JP, Khan PM, et al. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-5.
7. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-6.
8. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758-62.
9. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-8.
10. Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37: 641-5.
11. Wullenweber HP, Sutter C, Autschbach F, et al. Evaluation of Bethesda guidelines in relation to microsatellite instability. Dis Colon Rectum 2001; 44: 1281-9.
12. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293: 1986-94.
13. Rodriguez-Moranta F, Castells A, Andreu M, et al. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol 2006; 101: 1104-11.
14. Wolf B, Gruber S, Henglmueller S, et al. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients. Int J Cancer 2006; 118: 1465-70.
15. Mangold E, Pagenstecher C, Friedl W, et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 2005; 116: 692-702.
16. Engel C, Forberg J, Holinski-Feder E, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006; 118: 115-22.
17. Walsh MD, Buchanan DD, Pearson SA, et al. Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Mod Pathol 2012; 25: 722-30.
18. Yurgelun MB, Goel A, Hornick JL, et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) 2012; 5: 574-82.